Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy

Drug Metabolism and Disposition

Volumn 44, Issue 11, 2016, Pages 1832-1838

  Fokina, Valentina M ^a   Xu, Meixiang ^a   Rytting, Erik ^a   Abdel Rahman, Sherif Z ^a   West, Holly ^a   Oncken, Cheryl ^b   Clark, Shannon M ^a   Ahmed, Mahmoud S ^a   Hankins, Gary D V ^a   Nanovskaya, Tatiana N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DRUG METABOLITE; ERYTHROHYDROBUPROPION; RADAFAXINE; THREOHYDROBUPROPION; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; HYDROBUPROPION;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CREATININE CLEARANCE; CYP2B6 GENE; CYP2C19 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; GESTATIONAL AGE; GLUCURONIDATION; HETEROZYGOTE; HUMAN; KIDNEY BLOOD FLOW; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHENOTYPE; PREGNANCY; PREGNANT WOMAN; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; STEADY STATE; THIRD TRIMESTER PREGNANCY; TREND STUDY; ADULT; ALLELE; ANALOGS AND DERIVATIVES; GENETICS; METABOLISM; YOUNG ADULT;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C19; FEMALE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85015381063     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.071530     Document Type: Article

References (39)

1. Abernethy DR, Divoll M, Ochs HR, Ameer B, and Greenblatt DJ (1982) Increased metabolic clearance of acetaminophen with oral contraceptive use. Obstet Gynecol 60: 338-341.
2. Anderson GD (2005) Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 44:989-1008.
3. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, and Jacob P, 3rd (2013) Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 23:135-141.
4. Chen Y, Liu HF, Liu L, Nguyen K, Jones EB, and Fretland AJ (2010) The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 40:536-546.
5. Costantine MM (2014) Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 5:65.
6. Dickmann LJ and Isoherranen N (2013) Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metab Dispos 41:270-274.
7. Faul F, Erdfelder E, Buchner A, and Lang A-G (2009) Statistical power analyses using G∗Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149-1160.
8. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, and Schroeder DH (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21:127-135.
9. Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López M, Peñas-Lledó E, and LLerena A (2016) Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. Pharmacogenomics J 16:113-123.
10. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
11. Gufford BT, Lu JB, Metzger IF, Jones DR, and Desta Z (2016) Stereoselective glucuronidation of bupropion metabolites in vitro and in vivo. Drug Metab Dispos 44:544-553.
12. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
13. Høiseth G, Haslemo T, Uthus LH, and Molden E (2015) Effect of CYP2B6∗6 on steady-state serum concentrations of bupropion and hydroxybupropion in psychiatric patients: a study based on therapeutic drug monitoring data. Ther Drug Monit 37:589-593.
14. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, and Johnston JA (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
15. Jefferson JW, Pradko JF, and Muir KT (2005) Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695.
16. Jeong H, Choi S, Song JW, Chen H, and Fischer JH (2008) Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38:62-75.
17. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, and Unadkat JD (2013) A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos 41:801-813.
18. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, and Brockmöller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
19. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, and Lai AA (1985) Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 38:586-589.
20. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
21. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, and Tyndale RF (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62:635-641.
22. Loebstein R, Lalkin A, and Koren G (1997) Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328-343.
23. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, et al. (2003) Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 59:553-557.
24. Molnari JC and Myers AL (2012) Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550-561.
25. Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, and Ingelman-Sundberg M (2010) Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol 78:886-894.
26. Ohman I, Luef G, and Tomson T (2008) Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 17:199-202.
27. Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, Oyigboja J, Back D, Khoo S, and Owen A (2015) Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther 97:298-306.
28. Olagunju A, Owen A, and Cressey TR (2012) Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 13:1501-1522.
29. Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, and Paris BL (2010) System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet 25:16-27.
30. Petsalo A, Turpeinen M, and Tolonen A (2007) Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 21:2547-2554.
31. Raupach T and van Schayck CP (2011) Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 25:371-382.
32. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, Rytting E, Thummel K, Kelly EJ, Risler L, et al. (2016) Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol 56:581-589.
33. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, and Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317-323.
34. Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GD, Ahmed MS, and Nanovskaya TN (2010) Bupropion metabolism by human placenta. Biochem Pharmacol 79: 1684-1690.
35. Wang X, Vernikovskaya DI, Abdelrahman DR, Hankins GD, Ahmed MS, and Nanovskaya TN (2012) Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 70:320-329.
36. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, and Raistrick D (2005) Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 61:763-768.
37. Zanger UM and Klein K (2013) Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4:24.
38. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, and Tyndale RF (2012) CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 92:771-777.
39. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, and Tyndale RF (2014) Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos 42:1971-1977.